The Efficacy of Oxybutynin Chloride OROS in Patient-Reported Outcomes With Dose Escalation in Korean Overactive Bladder Patients

Trial Profile

The Efficacy of Oxybutynin Chloride OROS in Patient-Reported Outcomes With Dose Escalation in Korean Overactive Bladder Patients

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Sep 2013

At a glance

  • Drugs Oxybutynin (Primary)
  • Indications Overactive bladder
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutica
  • Most Recent Events

    • 20 May 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual initiation date changed from Sep 2007 to Sep 2006 as reported by ClinicalTrials.gov.
    • 20 May 2009 Actual patient number (320) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top